Welcome to our dedicated page for Respirerx Pharma news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on Respirerx Pharma stock.
Respirex Pharma (RSPI) delivers innovative therapeutic solutions through cutting-edge biopharmaceutical research. This news hub provides investors and industry professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company’s trajectory.
Access a centralized repository of press releases and verified news covering RSPI’s advancements in neurology, respiratory therapies, and translational medicine. Track critical updates including clinical trial progress, research partnerships, and peer-reviewed publication highlights that underscore the company’s scientific rigor.
Our curated collection ensures you stay informed about RSPI’s operational achievements without speculative commentary. Bookmark this page for efficient monitoring of earnings announcements, intellectual property developments, and collaborative ventures driving therapeutic innovation.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announced that Dr. Arnold Lippa, their Chief Scientific Officer, will speak at the 5th Meridian Drug Discovery Summit on November 7-8, 2022. He will present a talk on translational drug discovery and moderate a panel on diversity in drug discovery. The company focuses on treatments for neurological disorders, particularly ADHD, epilepsy, and obstructive sleep apnea, and is advancing drug candidates, including AMPAkines and GABAkines. Recent studies indicate promising clinical results for their lead compounds.
RespireRx Pharmaceuticals (OTCQ:RSPI) announced that Dr. Arnold Lippa, Executive Chairman and Chief Scientific Officer, will speak at the 5th International Cannabinoid-Derived Pharmaceuticals Summit from September 6-8, 2022, in Boston, MA. He will discuss the company's innovative lipid nanoparticle formulation technology aimed at repurposing dronabinol for obstructive sleep apnea (OSA) and other disorders. With over 29 million affected by OSA in the U.S., RespireRx is advancing clinical trials, including two Phase 2 studies showing promising results and plans for a Phase 3 study pending FDA discussions.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announced that Dr. Arnold Lippa, Chief Scientific Officer, spoke at the 2022 GRI Virtual Conference on April 23. He presented data on the potential use of AMPAkines for treating GRI disorders, which include cognitive deficits and treatment-resistant seizures. Dr. Lippa highlighted positive results of AMPAkines in animal models simulating GRI disorders. The company's EndeavourRx unit is focused on developing these low-impact AMPAkines. RespireRx aims to collaborate with CureGRIN Foundation to advance treatments for GRI disorders.
RespireRx Pharmaceuticals (OTCQB:RSPI) announced the publication of a manuscript highlighting potential novel treatments for tinnitus, a disorder affecting 10-15% of the global population. The review by RespireRx scientists suggests that loss of GABA neurotransmission may contribute to tinnitus, with older GABAkines showing some symptom improvement despite side effects. The manuscript aims to energize the search for effective treatments. Additionally, RespireRx is developing KRM-II-81, a GABAkine, which may offer a game-changing solution for tinnitus patients.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announced the filing of a provisional patent application for a novel lipid-based formulation technology (LFT) to enhance the solubility and bioavailability of poorly soluble drugs, with a focus on cannabinoids. Their ResolutionRx unit is advancing dronabinol formulations for obstructive sleep apnea (OSA), having completed two Phase 2 trials showing significant symptom reduction. The company plans further testing pending financing. Improved formulations aim to expand market opportunities for dronabinol, including potential treatments beyond current approvals.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announced the publication of a manuscript on D5-KRM-II-81, detailing its pharmacology. The study, led by Dr. Jeffrey M. Witkin, highlights the compound's ability to prevent seizures and its potential in treating pharmacoresistant epilepsy and pain. The findings support D5-KRM-II-81 as a promising orally-bioavailable option alongside KRM-II-81, which targets GABAA receptors. This advancement is crucial for addressing significant unmet medical needs in epilepsy and chronic pain treatment.
RespireRx Pharmaceuticals (OTCQ:RSPI) reviews its progress over the past year and outlines future plans. The company aims to unlock value through restructuring and two key platforms: pharmaceutical cannabinoids and neuromodulators. Recent achievements include successful trials with dronabinol for obstructive sleep apnea and advancements in AMPAkines and GABAkines for spinal cord injury and epilepsy treatments. However, financing challenges persist, particularly with the stock below the $0.02 offering price set for up to $7.5 million. Leadership changes were also noted, with Dr. Arnold Lippa stepping in as Interim CEO.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) has announced the publication of a manuscript detailing the pharmacology of its compound KRM-II-81, marking a significant advancement in developing GABAkines for neurological and psychiatric disorders. The paper describes KRM-II-81's efficacy against pharmacoresistant epilepsy and neuropathic pain, showcasing its low sedation effects and lack of tolerance development. The company's leadership sees potential in KRM-II-81 as a breakthrough treatment, moving towards IND enabling studies to address significant unmet medical needs.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announces participation in two upcoming investor conferences. CFO Jeff Margolis will present live at the Life Sciences Virtual Investor Conference on December 16, 2021, discussing the company’s vision and programs. Concurrently, President and CEO Tim Jones will present a pre-recorded video at the Biotech Showcase from January 17-19, 2022. These platforms offer insights into RespireRx's innovative treatments for psychiatric and neurological disorders, including obstructive sleep apnea and ADHD.
RespireRx Pharmaceuticals (OTCQB: RSPI) has published a pivotal review article on GABAkines, focusing on the development of positive allosteric modulators of GABAA receptors. This article highlights the potential of KRM-II-81, a GABAkine in development, to treat epilepsy and pain with reduced side effects compared to traditional benzodiazepines. KRM-II-81 shows promise in preclinical studies, demonstrating high anti-convulsant and analgesic activities without the risks of tolerance or dependence. The findings strongly support advancements in treatment options for neurological disorders.
